Patent SG-11201901389X-A (SG)
Title: Combination therapy with glutaminase inhibitors
Inventor: PARLATI FRANCESCO
IPC: C07D417/14
Filed: 2017-08-25
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/039544 Al 01 March 2018 (01.03.2018) W I P0 I P C T (51) International Patent Classification: A61K 31/433 (2006.01) C07D 417/02 (2006.01) Declarations under Rule 4.17: A61K 31/501 (2006.01) CO7D 417/14 (2006.01) — of inventorship (Rule 4.17(iv)) A61P 35/00 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/US2017/048581 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) 25 August 2017 (25.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/379,604 25 August 2016 (25.08.2016) US (71) Applicant: CALITHERA BIOSCIENCES, INC. [US/US]; 343 Oyster Point Boulevard, Suite 200, South San Francisco, California 94080 (US). (72) Inventors: PARLATI, Francesco; 1035 York Street, San _ Francisco, California 94110 (US). ORFORD, Keith; 3819 Charter Club Drive, Doylestown, Pennsylvania 18902 (US). — = WHITING, Sam, H.; 8920 Sand Point Way NE, Seattle, Washington 98115 (US). = Agent: HALSTEAD, David, P. et al.; Foley Hoag (74) — LLP, Seaport West, 155 Seaport Boulevard, Boston, MA _ = 02210-2600 (US). Designated States (unless otherwise indicated, for every = (81) — kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = = = = MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, — OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every = (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = — 1-1 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 71' 71' kin tz . M © (54) Title: COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS --.... ,1 (57) : The invention relates to methods of treating cancer or myeloproliferative diseaseswith a combination of a glutaminase 0 inhibitor and an anticancer agent selected from cabozantinib, crizotinib, and axitinib. The invention further relates to methods of treating N cancer or myeloproliferative diseases that are resistant to one or more anticancer agents.